🚀 VC round data is live in beta, check it out!
Türk İlaç Valuation Multiples
Discover revenue and EBITDA valuation multiples for Türk İlaç and similar public comparables like Oncocross, Annovis Bio, BGM Group, TScan Therapeutics and more.
Türk İlaç Overview
About Türk İlaç
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.
Founded
2010
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$126M
Türk İlaç Financials
Türk İlaç reported last fiscal year revenue of $57M and EBITDA of $17M.
In the same fiscal year, Türk İlaç generated $18M in gross profit, $17M in EBITDA, and $2M in net income.
Türk İlaç P&L
In the most recent fiscal year, Türk İlaç reported revenue of $57M and EBITDA of $17M.
Türk İlaç expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $57M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $18M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 31% | XXX | XXX | XXX |
| EBITDA | — | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 21% | XXX | XXX | XXX |
| Net Profit | — | XXX | $2M | XXX | XXX | XXX |
| Net Margin | — | XXX | 3% | XXX | XXX | XXX |
| Net Debt | — | — | $37M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Türk İlaç Stock Performance
Türk İlaç has current market cap of $65M, and enterprise value of $126M.
Market Cap Evolution
Türk İlaç's stock price is $0.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $126M | $65M | 2.4% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTürk İlaç Valuation Multiples
Türk İlaç trades at 2.2x EV/Revenue multiple, and 7.3x EV/EBITDA.
Türk İlaç Financial Valuation Multiples
As of April 18, 2026, Türk İlaç has market cap of $65M and EV of $126M.
Equity research analysts estimate Türk İlaç's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Türk İlaç has a P/E ratio of 40.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $65M | XXX | $65M | XXX | XXX | XXX |
| EV (current) | $126M | XXX | $126M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 10.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.1x | XXX | XXX | XXX |
| P/E | — | XXX | 40.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Türk İlaç Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Türk İlaç Margins & Growth Rates
Türk İlaç's revenue in the last fiscal year grew by 34%.
Türk İlaç Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 170% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Türk İlaç Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Acrivon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Türk İlaç M&A Activity
Türk İlaç acquired XXX companies to date.
Last acquisition by Türk İlaç was on XXXXXXXX, XXXXX. Türk İlaç acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Türk İlaç
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTürk İlaç Investment Activity
Türk İlaç invested in XXX companies to date.
Türk İlaç made its latest investment on XXXXXXXX, XXXXX. Türk İlaç invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Türk İlaç
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Türk İlaç
| When was Türk İlaç founded? | Türk İlaç was founded in 2010. |
| Where is Türk İlaç headquartered? | Türk İlaç is headquartered in Turkey. |
| Is Türk İlaç publicly listed? | Yes, Türk İlaç is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Türk İlaç? | Türk İlaç trades under TRILC ticker. |
| When did Türk İlaç go public? | Türk İlaç went public in 2021. |
| Who are competitors of Türk İlaç? | Türk İlaç main competitors are Oncocross, Annovis Bio, BGM Group, TScan Therapeutics. |
| What is the current market cap of Türk İlaç? | Türk İlaç's current market cap is $65M. |
| What is the current revenue of Türk İlaç? | Türk İlaç's last fiscal year revenue is $57M. |
| What is the current EV/Revenue multiple of Türk İlaç? | Current revenue multiple of Türk İlaç is 2.2x. |
| Is Türk İlaç profitable? | No, Türk İlaç is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.